Novazyme Pharmaceuticals Overview
- Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$215M
Novazyme Pharmaceuticals General Information
Description
Developer of biotherapeutic products for the treatment of lysosomal storage disorders.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 353 Nassau Street
- Princeton, NJ 08540
- United States
Novazyme Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 27-Sep-2001 | $215M | 0000 | 00000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 18-Apr-2001 | 0000 | 0000 | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 19-Sep-2000 | $8M | $8M | Completed | Product Development |
Novazyme Pharmaceuticals Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Catalyst Health Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| HealthCare Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Morgan Stanley Expansion Capital | Growth/Expansion | Majority | 000 0000 | 000000 0 | |
| Strattech Partners | Venture Capital | Minority | 000 0000 | 000000 0 |